3/12
08:12 am
solv
Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance
Low
Report
Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance
3/5
09:33 am
solv
Solventum Co. (NYSE: SOLV) had its price target raised by analysts at Morgan Stanley from $73.00 to $80.00. They now have an "equal weight" rating on the stock.
Low
Report
Solventum Co. (NYSE: SOLV) had its price target raised by analysts at Morgan Stanley from $73.00 to $80.00. They now have an "equal weight" rating on the stock.
3/3
01:13 pm
solv
Solventum Co. (NYSE: SOLV) had its price target raised by analysts at Mizuho from $70.00 to $82.00. They now have a "neutral" rating on the stock.
Low
Report
Solventum Co. (NYSE: SOLV) had its price target raised by analysts at Mizuho from $70.00 to $82.00. They now have a "neutral" rating on the stock.
3/3
10:06 am
solv
Solventum Co. (NYSE: SOLV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $63.00 to $71.00. They now have a "sell" rating on the stock.
Low
Report
Solventum Co. (NYSE: SOLV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $63.00 to $71.00. They now have a "sell" rating on the stock.
2/28
01:52 pm
solv
Solventum Co. (NYSE: SOLV) had its price target raised by analysts at Wells Fargo & Company from $73.00 to $75.00. They now have an "equal weight" rating on the stock.
Low
Report
Solventum Co. (NYSE: SOLV) had its price target raised by analysts at Wells Fargo & Company from $73.00 to $75.00. They now have an "equal weight" rating on the stock.
2/28
08:36 am
solv
Solventum Co. (NYSE: SOLV) had its price target raised by analysts at Piper Sandler from $75.00 to $84.00. They now have a "neutral" rating on the stock.
Low
Report
Solventum Co. (NYSE: SOLV) had its price target raised by analysts at Piper Sandler from $75.00 to $84.00. They now have a "neutral" rating on the stock.
2/27
04:05 pm
solv
Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance
Low
Report
Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance
2/26
04:15 pm
solv
Solventum to Host Investor Day on Thursday, March 20, 2025, in New York City
Low
Report
Solventum to Host Investor Day on Thursday, March 20, 2025, in New York City
2/26
08:00 am
solv
Solventum Co. (NYSE: SOLV) had its price target raised by analysts at Bank of America Co. from $80.00 to $85.00. They now have a "neutral" rating on the stock.
Low
Report
Solventum Co. (NYSE: SOLV) had its price target raised by analysts at Bank of America Co. from $80.00 to $85.00. They now have a "neutral" rating on the stock.
2/25
08:39 am
solv
Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B
Medium
Report
Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B
2/11
08:00 am
solv
Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors
Low
Report
Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors
2/5
10:00 am
solv
Solventum Fluency for Imaging clinches top spot again: Ranked #1 Best in KLAS for Speech Recognition: Front-end Imaging
Low
Report
Solventum Fluency for Imaging clinches top spot again: Ranked #1 Best in KLAS for Speech Recognition: Front-end Imaging
1/30
04:05 pm
solv
Solventum to Report Fourth Quarter and Full Year Fiscal 2024 Earnings on February 27, 2025
Low
Report
Solventum to Report Fourth Quarter and Full Year Fiscal 2024 Earnings on February 27, 2025
1/8
01:01 pm
solv
Trian Issues Open Letter to Solventum Shareholders
Low
Report
Trian Issues Open Letter to Solventum Shareholders
1/8
06:30 am
solv
The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing
Low
Report
The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing